These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29371619)

  • 1. Immunization with Transgenic Rodent Malaria Parasites Expressing Pfs25 Induces Potent Transmission-Blocking Activity.
    Sala KA; Angrisano F; Da DF; Taylor IJ; Churcher TS; Blagborough AM
    Sci Rep; 2018 Jan; 8(1):1573. PubMed ID: 29371619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Plasmodium berghei Pbg37 as Both a Pre- and Postfertilization Antigen with Transmission-Blocking Potential.
    Liu F; Li L; Zheng W; He Y; Wang Y; Zhu X; Tsuboi T; Cui L; Wang M; Cao Y
    Infect Immun; 2018 Aug; 86(8):. PubMed ID: 29866905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses.
    Jones RM; Chichester JA; Manceva S; Gibbs SK; Musiychuk K; Shamloul M; Norikane J; Streatfield SJ; van de Vegte-Bolmer M; Roeffen W; Sauerwein RW; Yusibov V
    Hum Vaccin Immunother; 2015; 11(1):124-32. PubMed ID: 25483525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional characterization of Plasmodium berghei PSOP25 during ookinete development and as a malaria transmission-blocking vaccine candidate.
    Zheng W; Liu F; He Y; Liu Q; Humphreys GB; Tsuboi T; Fan Q; Luo E; Cao Y; Cui L
    Parasit Vectors; 2017 Jan; 10(1):8. PubMed ID: 28057055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites.
    Mizutani M; Iyori M; Blagborough AM; Fukumoto S; Funatsu T; Sinden RE; Yoshida S
    Infect Immun; 2014 Oct; 82(10):4348-57. PubMed ID: 25092912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Plasmodium berghei sexual stage antigen PSOP12 induces anti-malarial transmission blocking immunity both in vivo and in vitro.
    Sala KA; Nishiura H; Upton LM; Zakutansky SE; Delves MJ; Iyori M; Mizutani M; Sinden RE; Yoshida S; Blagborough AM
    Vaccine; 2015 Jan; 33(3):437-45. PubMed ID: 25454088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
    Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates.
    Lee SM; Wu CK; Plieskatt J; McAdams DH; Miura K; Ockenhouse C; King CR
    Malar J; 2016 Aug; 15(1):405. PubMed ID: 27515826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a Plasmodium berghei sexual stage antigen PbPH as a new candidate for malaria transmission-blocking vaccine.
    Kou X; Zheng W; Du F; Liu F; Wang M; Fan Q; Cui L; Luo E; Cao Y
    Parasit Vectors; 2016 Apr; 9():190. PubMed ID: 27038925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25.
    Mlambo G; Maciel J; Kumar N
    Infect Immun; 2008 May; 76(5):2018-24. PubMed ID: 18316385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
    Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A
    Malar J; 2007 Aug; 6():107. PubMed ID: 17686163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Viral-Vectored Multi-Stage Malaria Vaccine Regimen With Protective and Transmission-Blocking Efficacies.
    Yusuf Y; Yoshii T; Iyori M; Mizukami H; Fukumoto S; Yamamoto DS; Emran TB; Amelia F; Islam A; Syafira I; Yoshida S
    Front Immunol; 2019; 10():2412. PubMed ID: 31681301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of transmission-blocking potential of PvPSOP25 using transgenic murine malaria parasite and clinical isolates.
    Zhang B; Feng H; Zhao Y; Zhang D; Yu X; Li Y; Zeng Y; Thongpoon S; Roobsoong W; Wu Y; Liu F; Sattabongkot J; Min H; Cui L; Cao Y
    PLoS Negl Trop Dis; 2024 Jun; 18(6):e0012231. PubMed ID: 38865344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against Plasmodium vivax.
    Blagborough AM; Musiychuk K; Bi H; Jones RM; Chichester JA; Streatfield S; Sala KA; Zakutansky SE; Upton LM; Sinden RE; Brian I; Biswas S; Sattabonkot J; Yusibov V
    Vaccine; 2016 Jun; 34(28):3252-9. PubMed ID: 27177945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes.
    Patra KP; Li F; Carter D; Gregory JA; Baga S; Reed SG; Mayfield SP; Vinetz JM
    Infect Immun; 2015 May; 83(5):1799-808. PubMed ID: 25690099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials.
    Ramjanee S; Robertson JS; Franke-Fayard B; Sinha R; Waters AP; Janse CJ; Wu Y; Blagborough AM; Saul A; Sinden RE
    Vaccine; 2007 Jan; 25(5):886-94. PubMed ID: 17049690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of transmission-blocking vaccines simultaneously targeting pre- and post-fertilization antigens in the rodent malaria parasite Plasmodium yoelii.
    Zheng L; Pang W; Qi Z; Luo E; Cui L; Cao Y
    Parasit Vectors; 2016 Aug; 9(1):433. PubMed ID: 27502144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology.
    Li Y; Leneghan DB; Miura K; Nikolaeva D; Brian IJ; Dicks MD; Fyfe AJ; Zakutansky SE; de Cassan S; Long CA; Draper SJ; Hill AV; Hill F; Biswas S
    Sci Rep; 2016 Jan; 6():18848. PubMed ID: 26743316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of two sexual-stage antigens as bivalent transmission-blocking vaccines in rodent malaria.
    Yang F; Liu F; Yu X; Zheng W; Wu Y; Qiu Y; Jin Y; Cui L; Cao Y
    Parasit Vectors; 2021 May; 14(1):241. PubMed ID: 33962671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.
    Kumar R; Ray PC; Datta D; Bansal GP; Angov E; Kumar N
    Vaccine; 2015 Sep; 33(39):5064-71. PubMed ID: 26299750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.